A detailed history of Vanguard Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 9,930,926 shares of NBIX stock, worth $1.34 Billion. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,930,926
Previous 9,710,328 2.27%
Holding current value
$1.34 Billion
Previous $1.28 Billion 7.05%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$130.4 - $143.74 $28.8 Million - $31.7 Million
220,598 Added 2.27%
9,930,926 $1.37 Billion
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $16 Million - $20 Million
150,485 Added 1.57%
9,710,328 $1.28 Billion
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $1.02 Million - $1.27 Million
-10,875 Reduced 0.11%
9,559,843 $1.08 Billion
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $2.4 Million - $2.81 Million
-26,814 Reduced 0.28%
9,570,718 $903 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $24.2 Million - $31.6 Million
257,237 Added 2.75%
9,597,532 $971 Million
Q4 2022

Feb 10, 2023

BUY
$106.72 - $127.06 $36.2 Million - $43.1 Million
339,332 Added 3.77%
9,340,295 $1.12 Billion
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $8.88 Million - $10.4 Million
96,489 Added 1.08%
9,000,963 $956 Million
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $9.63 Million - $12.7 Million
127,016 Added 1.45%
8,904,474 $868 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $763,115 - $998,633
-10,533 Reduced 0.12%
8,777,458 $823 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $8 Million - $10.7 Million
-100,479 Reduced 1.13%
8,787,991 $748 Million
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $8.29 Million - $9.52 Million
-96,151 Reduced 1.07%
8,888,470 $852 Million
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $803 Million - $919 Million
8,984,621 New
8,984,621 $874 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.